Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11099815 | 0.89 | NUDT1 (0.62) | NUDT1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2990823 | 0.83 | CDK1 (0.46) | NUDT1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22930422 | 0.83 | NUDT1 (0.60) | NUDT1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18134205 | 0.82 | NUDT1 (0.66) | NUDT1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10752783 | 0.81 | NUDT1 (0.60) | NUDT1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19890949 | 0.81 | MAPT (0.48) | NUDT1POLBSMN1; SMN2TLR8ALDH1A1 | |
| SCHEMBL9340530 | 0.80 | CDK1 (0.43) | NPC1RAB9ATLR8ALDH1A1KMT2A | |
| SCHEMBL10398846 | 0.79 | CDK1 (0.43) | NUDT1POLBNPC1RAB9ATLR8 | |
| SCHEMBL2457239 | 0.79 | ALDH1A1 (0.49) | NUDT1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18005314 | 0.78 | ALDH1A1 (0.46) | POLBNPC1RAB9ASMN1; SMN2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| EP-1648876-A1 | 5-HT SB 2B /SB RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012263-A1 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | NUDT1 1933/4885POLB 1520/4885NPC1 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.